<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086553</url>
  </required_header>
  <id_info>
    <org_study_id>BUG-2/CDA</org_study_id>
    <secondary_id>2008-006957-42</secondary_id>
    <nct_id>NCT01086553</nct_id>
  </id_info>
  <brief_title>9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease</brief_title>
  <official_title>Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg&#xD;
      budesonide three-times daily (TID) for the induction of remission in Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical remission, defined as a CDAI &lt; 150, at week 8 (LOCF)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment defined as CDAI &lt; 150 or CDAI reduction of &gt; 100 points</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">471</enrollment>
  <condition>Crohn´s Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9mg budesonide OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3mg budesonide TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>9mg budesonide OD</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>3mg budesonide TID</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent,&#xD;
&#xD;
          -  Age 18 to 75 years,&#xD;
&#xD;
          -  Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic&#xD;
             and histological, or endoscopic and radiological criteria [endoscopy not older than 12&#xD;
             months or if older, then clinical signs (e.g., pain localisation, pain intensity,&#xD;
             blood in stool) and behaviour (according to Montreal classification) should be&#xD;
             unchanged compared to former episodes],&#xD;
&#xD;
          -  Localisation of CD either in terminal ileum, coecum, ascending colon, or ileocolitis,&#xD;
&#xD;
          -  Active phase of disease (200 &lt; CDAI &lt; 400),&#xD;
&#xD;
          -  Negative pregnancy test in females of childbearing potential,&#xD;
&#xD;
          -  Women of child-bearing potential have to apply appropriate contraceptive methods,&#xD;
             e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of&#xD;
             contraception (e.g., use of a condom and spermicide), or partner has undergone&#xD;
             vasectomy. The investigator is responsible for determining whether the subject has&#xD;
             adequate birth control for study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known Crohn's lesions in the upper GI-tract (up to and including the jejunum) or&#xD;
             rectum with present symptoms,&#xD;
&#xD;
          -  Septic complications,&#xD;
&#xD;
          -  Evidence of infectious diarrhoea (i.e., pathogenic bacteria in stool culture),&#xD;
&#xD;
          -  Abscess, perforation, or active fistulas,&#xD;
&#xD;
          -  Ileostomy or colostomy,&#xD;
&#xD;
          -  Resection of more than 50 cm of the ileum,&#xD;
&#xD;
          -  Bowel surgery within the last 3 months,&#xD;
&#xD;
          -  Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis,&#xD;
             ileus),&#xD;
&#xD;
          -  Clinical signs of stricturing disease,&#xD;
&#xD;
          -  Subileus within the last 6 months (subileus with inflammatory hint allowed),&#xD;
&#xD;
          -  Suspicion of ileus, subileus or corresponding symptoms,&#xD;
&#xD;
          -  Parenteral or tube feeding,&#xD;
&#xD;
          -  Active peptic ulcer disease, local intestinal infection, or known established&#xD;
             cataract,&#xD;
&#xD;
          -  Diabetes mellitus, infection, osteoporosis, glaucoma, tuberculosis, or hypertension if&#xD;
             careful medical monitoring is not ensured,&#xD;
&#xD;
          -  Abnormal hepatic function (ALT or ALP &gt; 2.5 x upper limit of normal [ULN]), liver&#xD;
             cirrhosis, or portal hypertension,&#xD;
&#xD;
          -  Abnormal renal function (Cystatin C &gt; ULN),&#xD;
&#xD;
          -  Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,&#xD;
&#xD;
          -  History of cancer in the last five years (except for non-metastatic cancers, e.g.,&#xD;
             basalioma),&#xD;
&#xD;
          -  Treatment with immunosuppressants or anti-cancer drugs, e.g., 6 TG, methotrexate,&#xD;
             tacrolimus, cyclophosphamide, or cyclosporine within the last 3 months; in case of&#xD;
             treatment with azathioprine or 6 MP the drugs have to be used for maintenance of&#xD;
             remission only and dosage has to be unchanged within the last 3 months before baseline&#xD;
             visit and during the study,&#xD;
&#xD;
          -  Treatment with ketoconazole or other CYP3A inhibitors within the last month before&#xD;
             baseline visit,&#xD;
&#xD;
          -  Treatment with anti-TNF-alpha therapy within 3 months before baseline visit,&#xD;
&#xD;
          -  Conventional steroids (iv, po, rectal) within 2 weeks before baseline visit,&#xD;
&#xD;
          -  &gt; 6 mg/d budesonide po within 2 weeks before baseline visit,&#xD;
&#xD;
          -  Steroids for inhalation within 2 weeks before baseline visit,&#xD;
&#xD;
          -  Patients known to be steroid-refractory,&#xD;
&#xD;
          -  Treatment of study disease with oral antibiotics (e.g., metronidazole or&#xD;
             ciprofloxacin) within the last 2 weeks,&#xD;
&#xD;
          -  Application of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before&#xD;
             baseline visit except ≤ 350 mg/d or short-term acetylsalicylic acid (paracetamol is&#xD;
             allowed),&#xD;
&#xD;
          -  Known intolerance/hypersensitivity to study drug,&#xD;
&#xD;
          -  Well-founded doubt about the patient's cooperation, e.g., because of addiction to&#xD;
             alcohol or drugs,&#xD;
&#xD;
          -  Existing or intended pregnancy or breast-feeding,&#xD;
&#xD;
          -  Participation in another clinical trial within the last 30 days, simultaneous&#xD;
             participation in another clinical trial, or previous participation in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Dignass, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Klinik I - Markus-Krankenhaus - Frankfurter Diakonie-Kliniken</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Med. Klinik I - Markus-Krankenhaus - Frankfurter Diakonie-Kliniken</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Dignass A, Stoynov S, Dorofeyev AE, Grigorieva GA, Tomsová E, Altorjay I, Tuculanu D, Bunganič I, Pokrotnieks J, Kupčinskas L, Dilger K, Greinwald R, Mueller R; International Budenofalk Study Group. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial. J Crohns Colitis. 2014 Sep;8(9):970-80. doi: 10.1016/j.crohns.2014.01.021. Epub 2014 Feb 15.</citation>
    <PMID>24534142</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn´s disease</keyword>
  <keyword>budesonide</keyword>
  <keyword>induction of remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

